| Trial ID: | L4167 |
| Source ID: | NCT00950534
|
| Associated Drug: |
Insulin Glargine (Hoe901)
|
| Title: |
Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care
|
| Acronym: |
RELIANCE
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: INSULIN GLARGINE (HOE901)|DRUG: Oral Anti Diabetics (OAD)
|
| Outcome Measures: |
Primary: The percentage of patients achieving glycosylated haemoglobin (HbA1c) levels < or = 7.0%, From week 0 to week 24 | Secondary: Time required to reach the target HbA1c level of < or = 7%, From week 0 to week 24|The percentage of patients achieving two consecutive on treatment HbA1c measurements of < or = 7.0%, From week 0 to week 24|Decrease in mean HbA1c level, At week 24|Decrease in mean Fasting Plasma Glucose (FPG), At week 24|Mean change in body weight, At week 24
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
25
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-07
|
| Completion Date: |
2010-08
|
| Results First Posted: |
|
| Last Update Posted: |
2011-11-10
|
| Locations: |
Sanofi-Aventis Administrative Office, Macquarie Park, Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT00950534
|
